S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
NASDAQ:SYBX

Synlogic (SYBX) Stock Forecast, Price & News

$0.33
-0.01 (-2.91%)
(As of 09/22/2023 ET)
Compare
Today's Range
$0.31
$0.36
50-Day Range
$0.25
$0.54
52-Week Range
$0.24
$1.35
Volume
79,905 shs
Average Volume
184,258 shs
Market Capitalization
$22.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.33

Synlogic MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,796.2% Upside
$6.33 Price Target
Short Interest
Healthy
0.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.60mentions of Synlogic in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.92) to ($0.91) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.50 out of 5 stars

Medical Sector

185th out of 966 stocks

Pharmaceutical Preparations Industry

68th out of 450 stocks


SYBX stock logo

About Synlogic (NASDAQ:SYBX) Stock

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase II clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

SYBX Price History

SYBX Stock News Headlines

MarketBeat's Top 5 Stock Picks - Just Released
MarketBeat has just released five new trading ideas to All Access subscribers, but Tesla, Apple, and Netflix didn't make the cut. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. Now, MarketBeat thinks these five stocks may be even better buys.
Synlogic (SYBX) Receives a Buy from H.C. Wainwright
Expert Ratings for Synlogic
MarketBeat's Top 5 Stock Picks - Just Released
MarketBeat has just released five new trading ideas to All Access subscribers, but Tesla, Apple, and Netflix didn't make the cut. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. Now, MarketBeat thinks these five stocks may be even better buys.
The Latest Analyst Ratings for Synlogic
H.C. Wainwright Remains a Buy on Synlogic (SYBX)
SVB Securities Keeps Their Buy Rating on Synlogic (SYBX)
What 6 Analyst Ratings Have To Say About Synlogic
H.C. Wainwright Sticks to Its Buy Rating for Synlogic (SYBX)
See More Headlines
Receive SYBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Synlogic and its competitors with MarketBeat's FREE daily newsletter.

SYBX Company Calendar

Last Earnings
8/10/2023
Today
9/23/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SYBX
Employees
72
Year Founded
2013

Price Target and Rating

Average Stock Price Forecast
$6.33
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+1,796.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-66,150,000.00
Net Margins
-6,573.82%
Pretax Margin
-6,572.91%

Debt

Sales & Book Value

Annual Sales
$1.18 million
Book Value
$1.17 per share

Miscellaneous

Free Float
63,109,000
Market Cap
$22.91 million
Optionable
Not Optionable
Beta
0.96

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Aoife M. Brennan BAO (Age 47)
    BCh, M.D., MB, MMSc, Pres, CEO & Director
    Comp: $872.09k
  • Mr. Michael Jensen
    Chief Financial Officer
  • Mr. Antoine Awad (Age 43)
    Chief Operating Officer
    Comp: $566.55k
  • Dr. Timothy K. Lu M.D. (Age 42)
    Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Dr. James J. Collins Ph.D. (Age 57)
    Co-Founder & Member of Scientific Advisory Board
  • Mr. Brendan St. Amant
    Gen. Counsel & Corp. Sec.
  • Mr. Ajay Munshi
    VP of Corp. Devel.
  • Mr. Adam Thomas
    Chief People Officer
  • Dr. Caroline B. Kurtz Ph.D.
    Chief Devel. Officer
  • Ms. Molly Harper (Age 46)
    Chief Bus. Officer













SYBX Stock - Frequently Asked Questions

Should I buy or sell Synlogic stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SYBX shares.
View SYBX analyst ratings
or view top-rated stocks.

What is Synlogic's stock price forecast for 2023?

3 Wall Street research analysts have issued 12-month price objectives for Synlogic's stock. Their SYBX share price forecasts range from $5.00 to $8.00. On average, they predict the company's share price to reach $6.33 in the next twelve months. This suggests a possible upside of 1,796.2% from the stock's current price.
View analysts price targets for SYBX
or view top-rated stocks among Wall Street analysts.

How have SYBX shares performed in 2023?

Synlogic's stock was trading at $0.76 at the beginning of 2023. Since then, SYBX stock has decreased by 56.1% and is now trading at $0.3340.
View the best growth stocks for 2023 here
.

Are investors shorting Synlogic?

Synlogic saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 192,400 shares, a decrease of 25.7% from the August 15th total of 259,100 shares. Based on an average trading volume of 188,100 shares, the short-interest ratio is presently 1.0 days. Approximately 0.4% of the shares of the stock are sold short.
View Synlogic's Short Interest
.

When is Synlogic's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our SYBX earnings forecast
.

How were Synlogic's earnings last quarter?

Synlogic, Inc. (NASDAQ:SYBX) announced its quarterly earnings results on Thursday, August, 10th. The biotechnology company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.05. The biotechnology company earned $0.04 million during the quarter, compared to the consensus estimate of $0.18 million. Synlogic had a negative trailing twelve-month return on equity of 85.18% and a negative net margin of 6,573.82%.

When did Synlogic's stock split?

Synlogic shares reverse split on the morning of Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 25th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What other stocks do shareholders of Synlogic own?
What is Synlogic's stock symbol?

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

Who are Synlogic's major shareholders?

Synlogic's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (0.44%), Harbor Capital Advisors Inc. (0.43%), Renaissance Technologies LLC (0.31%) and PVG Asset Management Corp (0.10%). Insiders that own company stock include Antoine Awad, Aoife Brennan and Michael Vangsted Jensen.
View institutional ownership trends
.

How do I buy shares of Synlogic?

Shares of SYBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Synlogic's stock price today?

One share of SYBX stock can currently be purchased for approximately $0.33.

How much money does Synlogic make?

Synlogic (NASDAQ:SYBX) has a market capitalization of $22.91 million and generates $1.18 million in revenue each year. The biotechnology company earns $-66,150,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis.

How can I contact Synlogic?

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The official website for the company is www.synlogictx.com. The biotechnology company can be reached via phone at (617) 401-9975, via email at liz@synlogictx.com, or via fax at 512-681-5201.

This page (NASDAQ:SYBX) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -